COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Price, Forecast & Analysis
USA - NASDAQ:COLL - US19459J1043 - Common Stock
COLL Key Statistics, Chart & Performance
The current stock price of COLL is 46.38 USD. In the past month the price increased by 39.66%. In the past year, price increased by 56.8%.
COLL Latest News, Press Relases and Analysis
COLL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.52 | 968.11B | ||
| JNJ | JOHNSON & JOHNSON | 18.81 | 470.23B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.12B | ||
| PFE | PFIZER INC | 8.06 | 146.63B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.41 | 98.98B | ||
| ZTS | ZOETIS INC | 19.11 | 53.70B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.17B | ||
| VTRS | VIATRIS INC | 4.68 | 12.72B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.92B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.08 | 7.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.86B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.90B |
Related stock screener links
About COLL
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Company Info
COLLEGIUM PHARMACEUTICAL INC
100 Technology Center Dr
Stoughton MASSACHUSETTS 02072 US
CEO: Joseph Ciaffoni
Employees: 357
Phone: 17817133699
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What does COLLEGIUM PHARMACEUTICAL INC do?
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Can you provide the latest stock price for COLLEGIUM PHARMACEUTICAL INC?
The current stock price of COLL is 46.38 USD. The price decreased by -2.05% in the last trading session.
Does COLL stock pay dividends?
COLL does not pay a dividend.
What is the ChartMill technical and fundamental rating of COLL stock?
COLL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is COLLEGIUM PHARMACEUTICAL INC (COLL) stock traded?
COLL stock is listed on the Nasdaq exchange.
What is COLLEGIUM PHARMACEUTICAL INC worth?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a market capitalization of 1.46B USD. This makes COLL a Small Cap stock.
Can you provide the short interest for COLL stock?
The outstanding short interest for COLLEGIUM PHARMACEUTICAL INC (COLL) is 16.91% of its float.
COLL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is one of the better performing stocks in the market, outperforming 90.93% of all stocks.
COLL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to COLL. While COLL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
COLL Financial Highlights
Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 7.19. The EPS increased by 30.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.13% | ||
| ROA | 2.28% | ||
| ROE | 15.62% | ||
| Debt/Equity | 3.27 |
COLL Forecast & Estimates
11 analysts have analysed COLL and the average price target is 45.49 USD. This implies a price decrease of -1.91% is expected in the next year compared to the current price of 46.38.
For the next year, analysts expect an EPS growth of 40.67% and a revenue growth 19.45% for COLL